References
- Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2012.
- Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2012.
- Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y. URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 2012.
- Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, . Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 2010; 53:295–315.
- Bohatyrewicz M, Urasinska E, Rozanski J, Ciechanowski K. Membranous glomerulonephritis may be associated with heavy marijuana abuse. Transplant Proc 2007; 39:3054–3056.
- Mazze RI, Trudell JR, Cousins MJ. Methoxyflurane metabolism and renal dysfunction: clinical correlation in man. Anesthesiology 1971; 35:247–252.
- Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 2012; 36: 360–371.